CADENCE SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cadence Pharmaceuticals, Inc. (CADX) Over the Proposed Sale of the Company to Mallinckrodt plc in a Cash Deal
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cadence Pharmaceuticals, Inc. (“Cadence” or the “Company”) (NasdaqGS: CADX) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Mallinckrodt in a cash deal valued at approximately $1.3 billion. Under the terms of the proposed transaction, Cadence’s stockholders will receive $14.00 for each share of Cadence common stock they own.
The investigation focuses on whether Cadence’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct an adequate and fair sales process prior to agreeing to this proposed transaction, whether and by how much this proposed transaction undervalues the Company to the detriment of Cadence’s shareholders.
If you own common stock in Cadence and wish to obtain additional information and protect your investments free of charge, please contact Juan E. Monteverde, Esq. either via e-mail at email@example.com or by telephone at (877) 247-4292 or (212) 983-9330.